Submission of Audited financial Results for the quarter and year ended 31st March, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Novelix Pharmaceuticals (formerly Trimurthi Ltd) reported annual revenue of Rs 13,233.88 Lakhs, a massive jump from Rs 3,071.44 Lakhs in the prior year (~331% increase). The company posted a net profit of Rs 255.66 Lakhs versus just Rs 8.45 Lakhs previously, reflecting profit growth exceeding 2,900%. For Q4 FY26, revenue stood at Rs 2,519.36 Lakhs with net profit of Rs 91.19 Lakhs. The auditor CVS Balachandra Rao & Co. issued an unmodified (clean) opinion on the financials. Cash flow from operations was negative at Rs -2,585.63 Lakhs for the year, indicating working capital pressure despite strong profitability. The company operates in a single segment: Pharmaceutical Research & Analysis and Manufacturing & Trading of Bulk Drugs.
The company shows exceptional top-line and bottom-line growth after a change in business activity. However, the negative operating cash flow raises concerns about cash conversion quality, and shareholders should monitor working capital management closely.